WallStreetZenWallStreetZen

NASDAQ: SUPN
Supernus Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

SUPN past earnings growth

How has SUPN's earnings growth performed historically?
Company
-33.8%
Industry
15.19%
Market
40.76%
SUPN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
SUPN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
SUPN's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

SUPN past revenue growth

How has SUPN's revenue growth performed historically?
Company
-7.35%
Industry
10.93%
Market
14.02%
SUPN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SUPN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SUPN's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SUPN earnings and revenue history

Current Revenue
$610.5M
Current Earnings
$25.6M
Current Profit Margin
4.2%

SUPN Return on Equity

Current Company
2.8%
Current Industry
10.3%
Current Market
-9.5%
SUPN's Return on Equity (2.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SUPN announces earnings.

SUPN Return on Assets

Current Company
1.7%
Current Industry
2.9%
SUPN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SUPN Return on Capital Employed

Current Company
4.1%
Current Industry
5.6%
SUPN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SUPN vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SUPN$610.54M$124.96M$25.62M+9.87%-24.45%
TARO$592.89M$65.76M$32.76M-1.65%-31.85%
TLRY$650.86M-$1.31B-$1.45B+36.86%N/A
AMRX$2.39B$438.73M$10.32M+10.34%-95.45%
IRWD$432.38M-$888.66M-$952.29M+6.87%N/A
View Top Pharmaceutical Stocks

Supernus Pharmaceuticals Earnings & Revenue FAQ

What were SUPN's earnings last quarter?

On Invalid Date, Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q3 2023 earnings per share (EPS) of -$0.29, up 1,066.67% year over year. Total Supernus Pharmaceuticals earnings for the quarter were -$15.98 million. In the same quarter last year, Supernus Pharmaceuticals's earnings per share (EPS) was $0.03.

If you're new to stock investing, here's how to buy Supernus Pharmaceuticals stock.

What was SUPN's earnings growth in the past year?

As of Q4 2023, Supernus Pharmaceuticals's earnings has grown -33.8% year over year. This is 48.99 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 15.19%. Supernus Pharmaceuticals's earnings in the past year totalled $25.62 million.

What was SUPN's revenue last quarter?

On Invalid Date, Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q3 2023 revenue of $153.88 million up 13.24% year over year. In the same quarter last year, Supernus Pharmaceuticals's revenue was $177.35 million.

What was SUPN's revenue growth in the past year?

As of Q4 2023, Supernus Pharmaceuticals's revenue has grown -7.35% year over year. This is 18.28 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.93%. Supernus Pharmaceuticals's revenue in the past year totalled $610.54 million.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.